The effect of TMAO on aging-associated cardiovascular and metabolic pathways and emerging therapies.
Abstract
Metabolites produced by gut microbes have been linked to the pathophysiology of several disorders, including cardiovascular disease (CVD), such as atherosclerosis, hypertension, heart failure, and myocardial infarction. Trimethylamine-N-oxide (TMAO) is a primary diet-induced metabolite generated by the gut microbiota. TMAO is involved in dysregulation of bile acid and cholesterol metabolism, which promotes oxidative stress, inflammation, and endothelial dysfunction leading to vascular damages. Aging is usually associated with cardio-metabolic diseases, and the increasing evidence reveals that TMAO is linked with an increased risk of CVD in elderly. However, the exact relationship between plasma TMAO levels, the risk of CVD, and aging remains unclear. In this review, we explore the three-dimensional relationship between TMAO, aging, and CVD. Moreover, we discussed the new therapies used to reduce TMAO levels in aging and CVD.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper explores the relationship between TMAO levels, aging, and cardiovascular disease, suggesting that targeting TMAO could be a therapeutic approach for age-related cardiovascular issues. The focus on TMAO's role in aging-associated cardiovascular pathways indicates a potential avenue for addressing root causes of age-related diseases.
Author of this paper? Send a correction.